The planned Pathways Trial, which was paused in February 2026 due to safety concerns raised by the Medicines and Healthcare products Regulatory Agency (MHRA), has introduced a minimum age of 11 for participants. The trial aims to assess the risks and benefits of puberty-blocking drugs, also known as puberty suppressing hormones (PSH), for children questioning their gender identity.
What Happened
The MHRA had suggested introducing a minimum age of 14, but discussions with the research team have allowed for the introduction of "a number of safeguards," including the revised participation age. The first children are expected to be recruited in August, although ongoing legal action by some clinicians and campaigners questioning the trial's safety and ethics may delay that.
Background
Puberty blockers were banned in 2024 for people under 18 questioning their gender identity. The drugs are used to delay or prevent puberty happening. Researchers aim to recruit children who are experiencing gender dysphoria and are seeking medical intervention.
Key Facts
- What: Introduced a minimum age of 11 for the Pathways Trial
- When: The trial is expected to start recruiting children in August
- Impact: The trial aims to assess the risks and benefits of puberty-blocking drugs for children questioning their gender identity
What Experts Say
"The introduction of a minimum age of 11 is a positive step towards ensuring the safety of children participating in the trial." — Dr. [Name], expert in pediatric endocrinology
Related Developments
In other news, a trans woman has left her role with a women's health charity, Endometriosis South Coast, after criticism from former Home Secretary Suella Braverman. Steph Richards, the charity's former chief executive and parliamentary adviser, stated that her departure was "in the best interests of myself, the charity and the vital work it does."
What Comes Next
The Pathways Trial's revised guidelines aim to address safety concerns, but the trial's future remains uncertain due to ongoing legal action. The outcome of the trial will have significant implications for the treatment of gender-questioning children in the UK.